Asset Details
Do you wish to reserve the book?
Acute myeloid leukaemia in adults
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Acute myeloid leukaemia in adults
Do you wish to request the book?
Acute myeloid leukaemia in adults
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Acute myeloid leukaemia in adults
2013
Overview
The outlook for patients with acute myeloid leukaemia has improved in the past 30 years. Unlike other cancers, much of this progress is attributable to refinement of supportive treatment, rather than the introduction of new drugs. New antibacterial and antifungal agents, antiemetics, and improved transfusion support have decreased the rate of early death, and morbidity and mortality from allogeneic stem cell transplantation has been substantially reduced. However, more than half of young adult patients and about 90% of older patients still die from their disease. Refractoriness to initial induction treatment and, more frequently, relapse after complete remission, are still the main obstacles to cure. Accordingly, new treatment approaches with mechanisms of action different from those of conventional chemotherapy are needed. Our knowledge of the various chromosomal and molecular abnormalities implicated in the pathogenesis of the many subtypes of the disease has greatly expanded; as a result, clinical research is moving towards the investigation of new non-cytotoxic agents in combination with chemotherapy. The goal is to target the molecular abnormalities identified at diagnosis; however, several aberrations can coexist in subclones of acute myeloid leukaemia, making the disease less likely to be inhibited by a single agent.
Publisher
Elsevier Ltd,Elsevier,Elsevier Limited
Subject
/ adults
/ Antineoplastic Combined Chemotherapy Protocols - administration & dosage
/ Biological and medical sciences
/ Bone Marrow Transplantation - methods
/ Bone Marrow Transplantation - mortality
/ death
/ Female
/ Hematologic and hematopoietic diseases
/ Hematopoietic Stem Cell Transplantation - methods
/ Hematopoietic Stem Cell Transplantation - mortality
/ Humans
/ Leukemia
/ Leukemia, Myeloid, Acute - diagnosis
/ Leukemia, Myeloid, Acute - epidemiology
/ Leukemia, Myeloid, Acute - therapy
/ Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
/ Male
/ Mutation
/ Neoplasm Recurrence, Local - mortality
/ Neoplasm Recurrence, Local - therapy
/ patients
/ relapse
